Improving diabetes care for breast cancer patients
Optimizing Delivery of Diabetes Management During Breast Cancer Care
This study tests if giving special diabetes care from a trained nurse to breast cancer patients can help them manage their diabetes better during treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 76 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 3 sites (Brooklyn, New York and 2 other locations) |
| Trial ID | NCT05565534 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance diabetes management for breast cancer patients who are also dealing with diabetes during their cancer treatment. It involves a nurse practitioner-led intervention where one group of patients receives specialized diabetes care from a trained nurse while the other group does not. The study will assess the effectiveness of this intervention by comparing outcomes between the two groups over a period of approximately 12 weeks. The goal is to determine if integrating diabetes care into oncology teams can improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have newly diagnosed invasive breast cancer and pre-diabetes or type 2 diabetes.
Not a fit: Patients receiving hospice care or those with type 1 diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better diabetes management and overall health outcomes for breast cancer patients with diabetes.
How similar studies have performed: While similar approaches have been explored, this specific intervention is novel in its focus on integrating diabetes care within oncology settings for breast cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed invasive cancer * Plan to receive neo-adjuvant or adjuvant chemotherapy, targeted therapy, hormonal therapy, or radiation at Weill Cornell Medicine (WCM) * Age 18+ years * Pre-diabetes OR type 2 diabetes. Treatment with antidiabetic medication OR * HbA1c greater than or equal to 5.7 OR * Random glucose greater than or equal to OR * Fasting blood glucose greater than or equal to 100 Exclusion Criteria: * Patients receiving hospice care * Type 1 diabetes
Where this trial is running
Brooklyn, New York and 2 other locations
- NewYork-Presbyterian Brooklyn Methodist Hospital — Brooklyn, New York, United States (Recruiting)
- New York-Presbyterian Queens — Flushing, New York, United States (Recruiting)
- Weill Cornell Medicine — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Laura C Pinheiro, PhD, MPH — Assistant Professor of Health Services Research in Medicine
- Study coordinator: Laura C Pinheiro, PhD, MPH
- Email: lcp2003@med.cornell.edu
- Phone: 646-962-5898
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.